Chen Su-fang, Li Hua
Department of Elderly Endocrinology, the First Affiliated Hospital of Zhengzhou University, China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2011 Aug;32(8):827-9.
To compare the blood glucose levels and variability of premixed insulin aspart (BIAsp 30) with human insulin premix (BHI 30) used in a twice a day injection regimen in elderly type 2 diabetes patients.
52 cases of inadequate glycemia controlled by oral anti-diabetic drugs were randomly divided into two groups, treated on a twice-daily regimen with BIAsp 30 (n = 26) and BHI 30 (n = 26) respectively. After achieving the target goal, a continuous glucose monitoring system (CGMS) was used to compare the blood glucose levels, blood glucose fluctuant coefficient (BGFC), postprandial glucose excursion (PPGE), and occurrence of hypoglycemia.
BIAsp 30 was as effective as BHI 30 in control glycaemia. Detected by CGMS, there was no statistical differences in blood glucose levels among pre-three main meals, post-lunch and the mean blood glucose (MBG) (all P > 0.05). The BGFC levels were significantly lower in the BIAsp 30 group than in the BHI 30 group [(1.69 ± 0.42) mmol/L vs. (2.07 ± 0.51) mmol/L, t = -3.013, P < 0.01]. The blood glucose increment over breakfast, dinner and the percentage of time at hyperglycaemia (BG > 11.1 mmol/L) were lower in the BIAsp 30 group than in the BHI 30 group [(2.89 ± 1.32) mmol/L vs. (3.83 ± 1.18) mmol/L, t = -2.705, P < 0.01; (2.69 ± 1.37) mmol/L vs. (3.55 ± 1.40) mmol/L, t = -2.232, P < 0.05; (6.21 ± 6.04)% vs. (10.01 ± 6.80)%, t = -2.132, P < 0.05]. The frequency of hypoglycemia was lower in the BIAsp 30 group than in the BHI 30 group, but there was no statistical difference (P > 0.05).
Pre-meal injection of BIAsp 30 in a twice-daily regimen could significantly improve the control of postprandial glucose level and reduce the overall glucose excursions so as to lower the risk of hypoglycaemia when compared to BHI 30.
比较老年2型糖尿病患者每日两次注射预混门冬胰岛素（BIAsp 30）与人胰岛素预混剂（BHI 30）的血糖水平及变异性。
选取52例口服降糖药血糖控制不佳的患者，随机分为两组，分别采用每日两次注射BIAsp 30（n = 26）和BHI 30（n = 26）治疗。达到目标血糖后，采用动态血糖监测系统（CGMS）比较血糖水平、血糖波动系数（BGFC）、餐后血糖波动幅度（PPGE）及低血糖发生情况。
BIAsp 30与BHI 30控制血糖效果相当。CGMS检测显示，三餐前、午餐后及平均血糖（MBG）水平差异无统计学意义（均P > 0.05）。BIAsp 30组BGFC水平显著低于BHI 30组[（1.69 ± 0.42）mmol/L vs.（2.07 ± 0.51）mmol/L，t = -3.013，P < 0.01]。BIAsp 30组早餐后、晚餐后血糖增加值及血糖高于11.1 mmol/L的时间百分比均低于BHI 30组[（2.89 ± 1.32）mmol/L vs.（3.83 ± 1.18）mmol/L，t = -2.705，P < 0.01；（2.69 ± 1.37）mmol/L vs.（3.55 ± 1.40）mmol/L，t = -2.232，P < 0.05；（6.21 ± 6.04）% vs.（10.01 ± 6.80）%，t = -2.132，P < 0.05]。BIAsp 30组低血糖发生频率低于BHI 30组，但差异无统计学意义（P > 0.05）。
与BHI 30相比，老年2型糖尿病患者每日两次餐前注射BIAsp 30可显著改善餐后血糖控制，减少整体血糖波动，降低低血糖风险。
